Evogene

Evogene Ltd. is a computational biology company operating with its subsidiaries in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. Its activities include agricultural work such as seed traits and ag-chemicals, and the design of novel small molecules for drug development using ChemPass AI, a computational generative AI engine. The company also focuses on the development and commercialization of castor bean seeds for industrial uses, and on medical cannabis products. It collaborates with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD), and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. Evogene was incorporated in 1999 and is headquartered in Rehovot, Israel.